Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Oct 04, 2018 9:44am

140 Views

Post# 28743685

RE:RE:Patient numbers

bigd1986 wrote: overall i thought the call went well although like yourselve i was annoyed not to get any specific patient number. i am very pleased that we are already profitable but getting patient numbers would have been the icing on the cake. mainly just to show the RBC dude that he needs to clearly re-think his entire thesis

Sure I agree with you, I feel really comfortable with what I heard today.

Bullboard Posts

Visionstate set to leverage success in the U.S. market